When benzodiazepine-induced neurological dysfunction (BIND) is misdiagnosed as functional neurological disorder (FND), the record does not quietly correct itself. It travels with the patient, shaping how every subsequent clinician interprets new symptoms, which specialists will accept the referral, and whether insurers will cover care. For patients carrying the functional label, that drift has practical consequences, and it is worth separating why the misdiagnosis happens from what can actually be done about it at the documentation level.
What BIND Actually Is
BIND, as described in the 2023 paper by Ritvo and colleagues, refers to the persistent neurological, cognitive, and autonomic symptoms that can follow prolonged benzodiazepine exposure — including in patients who tapered slowly and appropriately. Common features include sensory hypersensitivity (light, sound, touch), tremor, myoclonus, paresthesias, cognitive slowing, word-finding difficulty, autonomic instability, muscle pain, tinnitus, and protracted insomnia. The working mechanistic model invokes durable changes in GABA-A receptor function plus secondary neuroinflammation and autonomic dysregulation. BIND is iatrogenic by definition and temporally anchored: symptoms emerge in the context of benzodiazepine use, dose reductions, or discontinuation.
What FND Actually Is
Functional neurological disorder is, under current diagnostic frameworks, a positive diagnosis. It is no longer “everything organic has been ruled out.” It is made on the basis of specific rule-in signs — Hoover’s sign for functional weakness, tremor entrainment for functional tremor, tubular vision fields for functional visual loss, distractibility of movement disorders, and so on. The DSM-5-TR criteria explicitly require clinical findings that show incompatibility between the symptom and recognized neurological disease.
In practice, the diagnosis is not always arrived at that carefully. Patients still receive an FND label when a neurologist finds no structural lesion on imaging, no paroxysmal activity on EEG, and no clear fit to a standard syndrome, and when the clinician defaults to a functional interpretation instead of reconsidering the history. That default is where BIND patients get caught.
Why the Collision Happens
Three features of BIND make it vulnerable to being reclassified as FND.
First, structural imaging is typically normal. There is no MRI finding for BIND; brain parenchyma and white matter look unremarkable. EEGs do not show epileptiform activity. If a clinician treats “normal scan plus functional-appearing symptom” as diagnostic for FND, the conclusion is effectively written into the workflow.
Second, some BIND signs can superficially resemble functional ones. Waxing and waning tremor, variability with attention, fluctuation across days, and partial improvement with reassurance are all real phenomena in BIND, and they are also features commonly cited in FND. A clinician unfamiliar with BIND may read these as functional rule-in signs when they are in fact features of a heterogeneous neuromodulatory syndrome.
Third, the iatrogenic history is frequently incomplete in the chart. If a patient’s long-term benzodiazepine use and recent taper are not front-and-center in the history of present illness, the clinician may simply not connect the neurological picture to the medication history. Even when the history is recorded, the taper is often framed as “completed uneventfully months ago,” which most neurologists are not trained to weight as an active variable.
Documentation Advocacy: What Actually Changes the Record
For patients who want the record to reflect what is actually going on, several interventions are more useful than arguing diagnosis during a visit.
Build the medication timeline in writing. A one-page document listing benzodiazepine exposure (drug, dose, duration, taper schedule, discontinuation date) with corresponding symptom onset and trajectory does more work than any in-visit explanation. Ask that it be scanned into the chart rather than summarized verbally.
Ask for the word BIND to appear, with its expansion and citation. Clinicians write what they are given. Providing a short note — “The patient’s presentation is consistent with benzodiazepine-induced neurological dysfunction (BIND), as described in Ritvo et al., 2023” — gives the chart a searchable term that future clinicians can act on. It also preserves the iatrogenic framing.
If an FND diagnosis is already in the record, request an amendment under HIPAA. The Privacy Rule (45 CFR 164.526) gives patients the right to request amendment of records they believe are inaccurate. The request must be in writing, and the provider may decline, but a declined amendment request remains in the chart alongside the original, which partly accomplishes the documentation goal. Frame the request factually: the existing diagnosis does not reflect the medication history and symptom chronology, and ask that BIND terminology be added alongside or as correction.
Ask the treating physician to document rule-out findings for FND when applicable. If Hoover’s sign is negative, tremor does not entrain, and the remainder of the FND rule-in battery is not present, ask that this be recorded affirmatively. A record that says “FND rule-in signs tested and not present” is different from a record that says “functional etiology suspected.”
Bring the primary literature to appointments. The Ritvo paper, the Maudsley Deprescribing Guidelines, and the Benzodiazepine Information Coalition’s clinical resources are not universally recognized, but they shift the conversation from “the patient believes benzos caused this” to “there is a published framework for this syndrome.” A neurologist who would not accept the patient’s framing may engage with the literature.
What Not to Do
Do not reject the FND label by arguing against it in visit. The mechanism that produced the label is often institutional — limited visit time, diagnostic default patterns, unfamiliarity with BIND — and will not be reversed by a single disagreement. The record is changed with paper, not with persuasion.
Do not avoid mental-health care out of fear that it confirms the functional framing. BIND routinely produces anxiety, depression, and trauma responses that warrant treatment in their own right. Treating those does not retroactively validate an FND diagnosis; the two are separate clinical questions.
A Note on Clinicians
This section is worth reading even for patients. Many neurologists who have applied the FND label have done so in good faith within a diagnostic framework that does not yet incorporate BIND. The path forward is clinician education — the Ritvo paper, the Benzodiazepine Information Coalition’s clinical resources, the Maudsley Deprescribing Guidelines — more than confrontation. Patients who bring these materials to appointments tend to find the label softened or removed over time as the clinical team becomes more familiar with the syndrome.